Related Experiment Video
Updated: Nov 8, 2025
Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Neonatal-onset Progressive Familial Intrahepatic Cholestasis (PFIC): first molecular study in Tunisian patients
Insights
This study identifies novel mutations in Progressive Familial Intrahepatic Cholestasis (PFIC) types 1 and 2 in Tunisian patients. These findings aid in diagnosing rare liver disorders and offer genetic insights for affected families.
Area of Science:
- Genetics
- Hepatology
- Pediatric Medicine
Background:
- Progressive Familial Intrahepatic Cholestasis (PFIC) comprises rare, inherited liver diseases.
- PFIC types 1 and 2, characterized by neonatal onset, stem from mutations in ATP8B1 and ABCB11 genes, respectively.
- Accurate molecular diagnosis is crucial for managing neonatal cholestasis.
Purpose of the Study:
- To describe clinical and genetic findings in four Tunisian patients with PFIC.
- To identify novel mutations associated with PFIC in this population.
- To evaluate the utility of advanced genetic sequencing for diagnosing neonatal cholestasis.
Main Methods:
- Clinical evaluation and genetic analysis of four Tunisian patients diagnosed with PFIC.
- Identification and characterization of mutations in ATP8B1 and ABCB11 genes.
- Review of diagnostic approaches for neonatal cholestasis.
Main Results:
- Three patients had PFIC type 2 and one had PFIC type 1, all presenting typical features.
- Newly identified mutations were found in all four patients.
- A recurrent mutation in ABCB11 was observed in PFIC type 2 patients, suggesting a founder effect in Tunisia.
- The PFIC type 1 patient exhibited a novel mutation and congenital hypothyroidism, indicating potential phenotypic variability.
Conclusions:
- Novel mutations in PFIC1 and PFIC2 were identified in Tunisian patients.
- A specific mutation in PFIC2 may facilitate future diagnoses in the Tunisian population.
- Next-generation sequencing gene panels offer a promising approach for early diagnosis and management of neonatal cholestasis.
Abstract:
Progressive familial intrahepatic is a heterogeneous group of rare autosomal recessive liver disorders. Neonatal onset is characteristic of the PFIC 1 and PFIC 2, which result from mutations in genes respectivelyATP8B1 and ABCB11. Four Tunisian patients, three of them with PFIC 2 and one with PFIC1, were described. They all had typical clinical and biological features. However, they all had newly reported mutations. The same mutation was found in the patients with PFIC2, which could facilitate the diagnosis in Tunisian patients suspected in the future. The patient diagnosed with PFIC1 had also a newly described mutation, with a probable phenotypic particularity that is congenital hypothyroidism. Advances are being made to establish a molecular diagnosis in neonatal onset cholestasis. Indeed, next generation sequencing gene panels (NGSGP) potentially decrease the need for invasive procedures in these patients, enable early initiation of treatment and adequate genetic counseling.
